JP7793122B2 - 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ - Google Patents

標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ

Info

Publication number
JP7793122B2
JP7793122B2 JP2020515282A JP2020515282A JP7793122B2 JP 7793122 B2 JP7793122 B2 JP 7793122B2 JP 2020515282 A JP2020515282 A JP 2020515282A JP 2020515282 A JP2020515282 A JP 2020515282A JP 7793122 B2 JP7793122 B2 JP 7793122B2
Authority
JP
Japan
Prior art keywords
peptide
cells
domain
antigen
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521000A5 (https=
JP2020521000A (ja
Inventor
ヴァレンティン ブリュッテル，
ヴィシュフーセン，ヨルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of JP2020521000A publication Critical patent/JP2020521000A/ja
Publication of JP2020521000A5 publication Critical patent/JP2020521000A5/ja
Priority to JP2023010057A priority Critical patent/JP2023052647A/ja
Priority to JP2025014951A priority patent/JP2025072445A/ja
Application granted granted Critical
Publication of JP7793122B2 publication Critical patent/JP7793122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020515282A 2017-05-23 2018-05-18 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ Active JP7793122B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023010057A JP2023052647A (ja) 2017-05-23 2023-01-26 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2025014951A JP2025072445A (ja) 2017-05-23 2025-01-31 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172444 2017-05-23
EP17172444.6 2017-05-23
PCT/EP2018/063100 WO2018215340A1 (en) 2017-05-23 2018-05-18 Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023010057A Division JP2023052647A (ja) 2017-05-23 2023-01-26 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ

Publications (3)

Publication Number Publication Date
JP2020521000A JP2020521000A (ja) 2020-07-16
JP2020521000A5 JP2020521000A5 (https=) 2021-02-04
JP7793122B2 true JP7793122B2 (ja) 2026-01-05

Family

ID=58778895

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020515282A Active JP7793122B2 (ja) 2017-05-23 2018-05-18 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2023010057A Pending JP2023052647A (ja) 2017-05-23 2023-01-26 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2025014951A Pending JP2025072445A (ja) 2017-05-23 2025-01-31 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023010057A Pending JP2023052647A (ja) 2017-05-23 2023-01-26 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
JP2025014951A Pending JP2025072445A (ja) 2017-05-23 2025-01-31 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ

Country Status (8)

Country Link
US (2) US20200157175A1 (https=)
EP (1) EP3630809A1 (https=)
JP (3) JP7793122B2 (https=)
KR (2) KR102748741B1 (https=)
CN (2) CN110945019B (https=)
AU (1) AU2018274545B2 (https=)
CA (1) CA3063959A1 (https=)
WO (1) WO2018215340A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112941030B (zh) * 2021-01-25 2023-08-08 吉林大学 一种抗原特异性Treg及其制备方法和应用
AU2023238308A1 (en) 2022-03-24 2024-10-10 Julius-Maximilians-Universität Würzburg Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
EP4249506A1 (en) 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
AU2023240382A1 (en) 2022-03-24 2024-11-14 Julius-Maximilians-Universität Würzburg Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
EP4249062A1 (en) 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
AU2024344683A1 (en) 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
WO2025061917A1 (en) 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
WO2025061913A1 (en) 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522695A (ja) 2007-03-07 2010-07-08 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
JP2012507995A (ja) 2008-11-07 2012-04-05 エイチエルエイ−ジー・テクノロジーズ Ｈｌａ−ｇポリペプチドおよびその医薬的使用
JP2014513948A (ja) 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞
US20150250862A1 (en) 2012-09-28 2015-09-10 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321222A1 (fr) 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
FR2794977B1 (fr) 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
US9234174B2 (en) * 2006-05-12 2016-01-12 Ospedale San Raffaele S.R.L. Tolerogenic dendritic cells, method for their production and uses therof
WO2009100135A2 (en) * 2008-02-04 2009-08-13 Medical College Georgia Research Institute, Inc. Hla-g compositions and methods of use thereof
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
CA2959821C (en) * 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522695A (ja) 2007-03-07 2010-07-08 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
JP2012507995A (ja) 2008-11-07 2012-04-05 エイチエルエイ−ジー・テクノロジーズ Ｈｌａ−ｇポリペプチドおよびその医薬的使用
JP2014513948A (ja) 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞
US20150250862A1 (en) 2012-09-28 2015-09-10 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Shang-Mian Yie, "HLA-G (major histocompatibility complex, class I, G)", ２０１７年４月２８日, [URL, 日本, 2017, 発行日
生化学，２００９年，第８１巻第３号，pp.１８９―１９９, 日本, 2009

Also Published As

Publication number Publication date
KR20250007053A (ko) 2025-01-13
JP2025072445A (ja) 2025-05-09
JP2023052647A (ja) 2023-04-11
KR102748741B1 (ko) 2024-12-31
AU2018274545A1 (en) 2019-12-05
AU2018274545B2 (en) 2023-09-21
KR20200021475A (ko) 2020-02-28
EP3630809A1 (en) 2020-04-08
JP2020521000A (ja) 2020-07-16
CA3063959A1 (en) 2018-11-29
CN119185534A (zh) 2024-12-27
WO2018215340A1 (en) 2018-11-29
US20200157175A1 (en) 2020-05-21
CN110945019A (zh) 2020-03-31
US20230416338A1 (en) 2023-12-28
CN110945019B (zh) 2025-04-04

Similar Documents

Publication Publication Date Title
JP7793122B2 (ja) 標的治療免疫調節のためのＭＨＣクラスＩｂ分子及びペプチドの組合せ
Speiser et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma–specific cytolytic T lymphocytes
KR102647696B1 (ko) Mage-a4 유래 펩티드를 인식하는 항원 결합성 단백질
Multhoff Heat shock proteins in immunity
CN115109141B (zh) 闭合蛋白-18.2特异性免疫受体和t细胞表位
CN107148427B (zh) 新型免疫原性肽
CN115955977A (zh) 用于过继性细胞疗法的多肽
RU2498993C2 (ru) Пептиды тем8 и содержащие их вакцины
LeMaoult et al. Synthetic HLA-G proteins for therapeutic use in transplantation
HUE026387T2 (en) Immunomodulation by C-type lectin
WO2010129895A2 (en) Cd133 epitopes
MX2011001883A (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
Kobayashi et al. Defining MHC class II T helper epitopes for WT1 tumor antigen
JP2018506287A (ja) Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９〜３７７位エピトープに特異的な完全ヒトＴ細胞受容体
JP2022512683A (ja) Ｈａ－１ｈに特異的な結合性タンパク質及びその使用
CN107002073A (zh) 肿瘤抗原肽
JP2017516752A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
Saha et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
JP2020055845A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
Housseau et al. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells
KR20240052028A (ko) 면역 제어법, 면역 제어용 핵산 조성물 및 그 용도
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
CN101812126B (zh) 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
Li et al. Priming of immune responses against transporter associated with antigen processing (TAP)‐deficient tumours: tumour direct priming
RU2794945C2 (ru) Антигенные рецепторы и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230126

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230126

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230214

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230221

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230407

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251029

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251210

R150 Certificate of patent or registration of utility model

Ref document number: 7793122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150